Systemic Therapies for Advanced Melanoma

被引：47

作者：

Bomar, Leonora ^{[1
]}

Senithilnathan, Aditi ^{[1
]}

Ahn, Christine ^{[1
]}

机构：

[1] Wake Forest Sch Med, Dept Dermatol, Winston Salem, NC USA

来源：

DERMATOLOGIC CLINICS | 2019年 / 37卷 / 04期

关键词：

Melanoma; Metastatic; Advanced; BRAF inhibitors; MEK inhibitors; Anti-PD1; agents; Ipilimumab; Chemotherapy; CUTANEOUS ADVERSE EVENTS; RANDOMIZED PHASE-III; RESECTED STAGE-III; METASTATIC MELANOMA; BRAF INHIBITORS; OPEN-LABEL; DOSE INTERFERON-ALPHA-2B; IMPROVED SURVIVAL; ADJUVANT THERAPY; MEK INHIBITORS;

D O I：

10.1016/j.det.2019.05.001

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The incidence of metastatic melanoma continues to increase each decade. Although surgical treatment is often curative for localized stage I and stage II disease, the median survival for patients with distant metastases is less than 1 year. The last 2 decades have witnessed a breakthrough in therapeutic options with the development of immune checkpoint inhibitors, small molecule targeted therapy, and oncolytic viral therapy. This article provides an overview of the treatment options available for advanced melanoma, including chemotherapy, targeted therapy, immunotherapy, interleukin-2, and oncolytic viral agents.

引用

页码：409 / +

页数：16

共 95 条

[1] The use of immunotherapy in the treatment of melanoma [J].

Achkar, Tala ;

Tarhini, Ahmad A. .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10

[2] Drug-Associated Dermatomyositis Following Ipilimumab Therapy A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade [J].

Ali, Shirwa Sheik ;

Goddard, Allison L. ;

Luke, Jason J. ;

Donahue, Hilary ;

Todd, Derrick J. ;

Werchniak, Andrew ;

Vleugels, Ruth Ann .

JAMA DERMATOLOGY, 2015, 151 (02) :195-199

[3] Photodynamic Therapy for Multiple Eruptive Keratoacanthomas Associated With Vemurafenib Treatment for Metastatic Melanoma [J].

Alloo, Allireza ;

Garibyan, Lilit ;

LeBoeuf, Nicole ;

Lin, George ;

Werchniak, Andrew ;

Hodi, F. Stephen, Jr. ;

Flaherty, Keith T. ;

Lawrence, Donald P. ;

Lin, Jennifer Y. .

ARCHIVES OF DERMATOLOGY, 2012, 148 (03) :363-366

[4] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[5] Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma [J].

Anforth, R. M. ;

Blumetti, T. C. M. P. ;

Kefford, R. F. ;

Sharma, R. ;

Scolyer, R. A. ;

Kossard, S. ;

Long, G. V. ;

Fernandez-Penas, P. .

BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (05) :1153-1160

[6] Systemic Retinoid Therapy for Chemoprevention of Nonmelanoma Skin Cancer in a Patient Treated With Vemurafenib [J].

Anforth, Rachael ;

Blumetti, Tatiana Cristina Moraes Pinto ;

Affandi, Azura Mohd ;

Fernandez-Penas, Pablo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (19) :E165-E167

[7] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].

Ascierto, Paolo A. ;

Del Vecchio, Michele ;

Robert, Caroline ;

Mackiewicz, Andrzej ;

Chiarion-Sileni, Vanna ;

Arance, Ana ;

Lebbe, Celeste ;

Bastholt, Lars ;

Hamid, Omid ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Garbe, Claus ;

Loquai, Carmen ;

Dreno, Brigitte ;

Thomas, Luc ;

Grob, Jean-Jacques ;

Liszkay, Gabriella ;

Nyakas, Marta ;

Gutzmer, Ralf ;

Pikiel, Joanna ;

Grange, Florent ;

Hoeller, Christoph ;

Ferraresi, Virginia ;

Smylie, Michael ;

Schadendorf, Dirk ;

Mortier, Laurent ;

Svane, Inge Marie ;

Hennicken, Delphine ;

Qureshi, Anila ;

Maio, Michele .

LANCET ONCOLOGY, 2017, 18 (05) :611-622

[8] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[9]

Babiker HM, 2017, ONCOLYTIC VIROTHER, V6, P11, DOI 10.2147/OV.S100072

[10] Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds [J].

Bellon, T. ;

Lerma, V. ;

Gonzalez-Valle, O. ;

Gonzalez Herrada, C. ;

de Abajo, F. J. .

BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (03) :621-624

← 1 2 3 4 5 6 7 8 9 10 →